## Wu-Chou Su

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8595250/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	27.0	3,530
2	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	1.6	2,854
3	AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1689-1699.	27.0	1,802
4	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	10.7	1,369
5	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncology, The, 2012, 13, 528-538.	10.7	904
6	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 521-536.	10.7	486
7	Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 2017, 35, 1288-1296.	1.6	470
8	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	10.7	418
9	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncology, The, 2012, 13, 539-548.	10.7	390
10	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncology, The, 2020, 21, 373-386.	10.7	300
11	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics, 2012, 44, 1330-1335.	21.4	286
12	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i> -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3101-3109.	1.6	252
13	Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non–Small Cell Lung Cancer. Radiology, 2012, 264, 559-566.	7.3	216
14	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. Journal of Thoracic Oncology, 2015, 10, 793-799.	1.1	199
15	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590.	1.6	189
16	Targeted Paclitaxel by Conjugation to Iron Oxide and Gold Nanoparticles. Journal of the American Chemical Society, 2009, 131, 66-68.	13.7	177
17	The 5p15.33 Locus Is Associated with Risk of Lung Adenocarcinoma in Never-Smoking Females in Asia. PLoS Genetics, 2010, 6, e1001051.	3.5	168
18	Circulating interleukinâ€6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. International Journal of Cancer, 2013, 132, 1977-1985.	5.1	155

#	Article	IF	CITATIONS
19	Noninvasive Saliva-based <i>EGFR</i> Gene Mutation Detection in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1117-1126.	5.6	146
20	Elucidating Quantum Confinement in Graphene Oxide Dots Based On Excitation-Wavelength-Independent Photoluminescence. Journal of Physical Chemistry Letters, 2016, 7, 2087-2092.	4.6	143
21	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732.	1.1	141
22	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1319-1327.	1.1	138
23	Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients. Clinical Cancer Research, 2005, 11, 2222-2228.	7.0	135
24	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer. Cancer Discovery, 2022, 12, 74-89.	9.4	133
25	PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. International Journal of Nanomedicine, 2012, 7, 4269.	6.7	123
26	Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology, 2019, 14, 553-559.	1.1	123
27	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	1.2	122
28	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6644-6652.	7.0	100
29	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine,the, 2017, 5, 891-902.	10.7	92
30	Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. Biochemical Pharmacology, 2012, 83, 1159-1171.	4.4	90
31	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
32	Metformin Enhances Cisplatin Cytotoxicity by Suppressing Signal Transducer and Activator of Transcription–3 Activity Independently of the Liver Kinase B1–AMP-Activated Protein Kinase Pathway. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 241-250.	2.9	89
33	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1907-1918.	1.1	85
34	Antibody-free isolation of rare cancer cells from blood based on 3D lateral dielectrophoresis. Lab on A Chip, 2015, 15, 2950-2959.	6.0	84
35	Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Annals of Hematology, 2004, 83, 270-275.	1.8	80
36	Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT1, and CAIX. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 53-61.	2.8	80

#	Article	IF	CITATIONS
37	Betulinic Acid Decreases Specificity Protein 1 (Sp1) Level via Increasing the Sumoylation of Sp1 to Inhibit Lung Cancer Growth. Molecular Pharmacology, 2012, 82, 1115-1128.	2.3	80
38	A New Photothermal Therapeutic Agent: Coreâ€Free Nanostructured Au <sub><i>x</i></sub> Ag <sub>1â~'<i>x</i></sub> Dendrites. Chemistry - A European Journal, 2008, 14, 2956-2964.	3.3	79
39	Expression of S100A4 and <i>Met:</i> Potential Predictors for Metastasis and Survival in Early-Stage Breast Cancer. Oncology, 2004, 66, 429-438.	1.9	78
40	Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells. PLoS ONE, 2011, 6, e21428.	2.5	77
41	R331W Missense Mutation of Oncogene <i>YAP1</i> Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. Journal of Clinical Oncology, 2015, 33, 2303-2310.	1.6	77
42	Proteomic analysis of human pleural effusion. Proteomics, 2005, 5, 1062-1074.	2.2	75
43	A Polymorphism in the <i>APE1</i> Gene Promoter is Associated with Lung Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 223-229.	2.5	75
44	An openâ€label, singleâ€arm, phase 2 trial of the poloâ€like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer, 2014, 120, 976-982.	4.1	75
45	Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Research and Treatment, 2007, 103, 167-175.	2.5	74
46	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations Journal of Clinical Oncology, 2012, 30, LBA7500-LBA7500.	1.6	74
47	Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer, 2011, 71, 28-33.	2.0	73
48	Proteomic Profiling of Human Pleural Effusion Using Two-Dimensional Nano Liquid Chromatography Tandem Mass Spectrometry. Journal of Proteome Research, 2005, 4, 1274-1286.	3.7	72
49	<scp>G</scp> enetic variants associated with longer telomere length are associated with increased lung cancer risk among neverâ€smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer, 2015, 137, 311-319.	5.1	72
50	Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer, 2012, 75, 228-234.	2.0	71
51	Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget, 2014, 5, 740-753.	1.8	71
52	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. Journal of Thoracic Oncology, 2022, 17, 411-422.	1.1	70
53	Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Molecular Cancer, 2010, 9, 309.	19.2	68
54	Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis. Journal of the Formosan Medical Association, 2019, 118, 215-222.	1.7	68

#	Article	lF	CITATIONS
55	Annexin A2 Silencing Induces G2 Arrest of Non-small Cell Lung Cancer Cells through p53-dependent and -independent Mechanisms. Journal of Biological Chemistry, 2012, 287, 32512-32524.	3.4	64
56	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study Journal of Clinical Oncology, 2017, 35, 2020-2020.	1.6	63
57	Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations Journal of Clinical Oncology, 2019, 37, 4117-4117.	1.6	63
58	A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periampullary Carcinomas. Chemotherapy, 2003, 49, 154-158.	1.6	61
59	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations Journal of Clinical Oncology, 2012, 30, LBA7500-LBA7500.	1.6	60
60	Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1093-1100.	0.8	58
61	Hormone replacement therapy and lung cancer risk in Chinese. Cancer, 2007, 110, 1768-1775.	4.1	53
62	Interactive Effect of Cigarette Smoking With Human 8-Oxoguanine DNA N-Glycosylase 1 (hOGG1) Polymorphisms on the Risk of Lung Cancer: A Case-Control Study in Taiwan. American Journal of Epidemiology, 2009, 170, 695-702.	3.4	53
63	Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers. Cancer Research, 2013, 73, 4028-4038.	0.9	53
64	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs, 2016, 34, 625-635.	2.6	52
65	Liquid biopsy genotyping in lung cancer: ready for clinical utility?. Oncotarget, 2017, 8, 18590-18608.	1.8	52
66	Risk factors for primary lung cancer among never smokers by gender in a matched case–control study. Cancer Causes and Control, 2013, 24, 567-576.	1.8	51
67	Global Oct4 target gene analysis reveals novel downstream <i>PTEN</i> and <i>TNC</i> genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Research, 2015, 43, 1593-1608.	14.5	51
68	Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. Frontiers in Neurology, 2020, 11, 634.	2.4	51
69	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naÃ <sup>-</sup> ve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 8060-8060.	1.6	51
70	Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414.	2.9	50
71	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics, 2016, 25, 620-629.	2.9	50
72	Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) Journal of Clinical Oncology, 2012, 30, 4007-4007.	1.6	50

#	Article	IF	CITATIONS
73	Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. Lung Cancer, 2017, 108, 183-191.	2.0	49
74	Water-Dissolvable Sodium Sulfate Nanowires as a Versatile Template for the Fabrication of Polyelectrolyte- and Metal-Based Nanotubes. Journal of the American Chemical Society, 2006, 128, 11606-11611.	13.7	48
75	Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer, 2011, 72, 280-286.	2.0	48
76	Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget, 2017, 8, 30844-30858.	1.8	48
77	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. Oncology, 2013, 85, 44-52.	1.9	46
78	A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1736-1744.	1.1	46
79	ATM polymorphisms and risk of lung cancer among never smokers. Lung Cancer, 2010, 69, 148-154.	2.0	45
80	Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. Journal of Thoracic Oncology, 2011, 6, 1066-1072.	1.1	45
81	Bimetallic nanoplasmonic gap-mode SERS substrate for lung normal and cancer-derived exosomes detection. Journal of the Taiwan Institute of Chemical Engineers, 2017, 80, 149-155.	5.3	45
82	Phase 1 study of capmatinib in METâ€positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Science, 2020, 111, 536-547.	3.9	44
83	Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells. Carcinogenesis, 2012, 33, 2065-2075.	2.8	43
84	Modularly Assembled Magnetite Nanoparticles Enhance in Vivo Targeting for Magnetic Resonance Cancer Imaging. Bioconjugate Chemistry, 2008, 19, 1972-1979.	3.6	42
85	Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control. Lung Cancer, 2009, 65, 371-376.	2.0	42
86	Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879758.	3.2	41
87	Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. Scientific Reports, 2020, 10, 6774.	3.3	41
88	Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis. Clinical Cancer Research, 2017, 23, 2335-2345.	7.0	40
89	Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia. Human Genetics, 2012, 131, 1197-1203.	3.8	39
90	Surfactant-Assisted Hollowing of Cu Nanoparticles Involving Halide-Induced Corrosion–Oxidation Processes. Chemistry - A European Journal, 2006, 12, 3805-3810.	3.3	37

#	Article	IF	CITATIONS
91	Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2Â in phorbol ester-treated non-small cell lung cancer A549 cells. Nucleic Acids Research, 2007, 36, 217-227.	14.5	37
92	Rasch models suggested the satisfactory psychometric properties of the World Health Organization Quality of Life—Brief among lung cancer patients. Journal of Health Psychology, 2017, 22, 397-408.	2.3	37
93	Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics, 2021, 11, 7029-7044.	10.0	37
94	Emerging platforms using liquid biopsy to detect <i>EGFR</i> mutations in lung cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1427-1440.	3.1	36
95	Chemotherapy with Cisplatin and Continuous Infusion of 5-Fluorouracil and Bleomycin for Recurrent and Metastatic Nasopharyngeal Carcinoma in Taiwan. Oncology, 1993, 50, 205-208.	1.9	35
96	Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Digestive Diseases and Sciences, 2001, 46, 1387-1392.	2.3	35
97	Handheld energy-efficient magneto-optical real-time quantitative PCR device for target DNA enrichment and quantification. NPG Asia Materials, 2016, 8, e277-e277.	7.9	35
98	Glycogen Synthase Kinase-3 and Omi/HtrA2 Induce Annexin A2 Cleavage followed by Cell Cycle Inhibition and Apoptosis. Molecular Biology of the Cell, 2009, 20, 4153-4161.	2.1	34
99	Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. Lung Cancer, 2009, 64, 251-256.	2.0	34
100	Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA). Human Genetics, 2015, 134, 333-341.	3.8	34
101	Aqueous nickel-nitrilotriacetate modified Fe3O4–NH3+nanoparticles for protein purification and cell targeting. Nanotechnology, 2006, 17, 4174-4182.	2.6	33
102	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer, 2018, 126, 133-138.	2.0	33
103	Combined Intrapleural and Intravenous Chemotherapy, and Pulmonary Irradiation, for Treatment of Patients with Lung Cancer Presenting with Malignant Pleural Effusion. Oncology, 2003, 64, 18-24.	1.9	32
104	Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—a longitudinal analysis. Supportive Care in Cancer, 2015, 23, 283-291.	2.2	31
105	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 452-459.	2.5	31
106	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors Journal of Clinical Oncology, 2014, 32, 2520-2520.	1.6	31
107	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <i>EGFR</i> -mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study Journal of Clinical Oncology, 2014, 32, 8017-8017.	1.6	31
108	Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Annals of Thoracic Surgery, 2001, 72, 1868-1876.	1.3	30

#	Article	IF	CITATIONS
109	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations Journal of Clinical Oncology, 2021, 39, 9008-9008.	1.6	30
110	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations. Cancer Discovery, 2022, 12, 1676-1689.	9.4	30
111	Longâ€ŧerm results of a phase <scp>II</scp> trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/Tâ€cell lymphoma. European Journal of Haematology, 2015, 94, 130-137.	2.2	29
112	Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors. Clinical Cancer Research, 2021, 27, 6393-6404.	7.0	29
113	<i>EGFR</i> L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients. Clinical Cancer Research, 2011, 17, 2149-2158.	7.0	28
114	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	1.9	28
115	Positive feedback regulation between IL10 and EGFR promotes lung cancer formation. Oncotarget, 2016, 7, 20840-20854.	1.8	28
116	Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. Lung Cancer, 2018, 125, 35-42.	2.0	28
117	Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers, 2020, 12, 2041.	3.7	28
118	High Percentage of <i>JAK2</i> Exon 12 Mutation in Asian Patients With Polycythemia Vera. American Journal of Clinical Pathology, 2010, 134, 266-270.	0.7	27
119	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study ofÂCeritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 609-617.	1.1	27
120	A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. Oncotarget, 2015, 6, 13671-13687.	1.8	26
121	The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS ONE, 2018, 13, e0192161.	2.5	26
122	Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma. Digestive Diseases and Sciences, 1998, 43, 2261-2266.	2.3	25
123	High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer, 2008, 62, 78-84.	2.0	25
124	Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages toward tumorâ€suppressing phenotype. International Journal of Cancer, 2018, 143, 1753-1763.	5.1	25
125	Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness. Cell Death and Disease, 2018, 9, 868.	6.3	25
126	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 663-673.	5.6	24

#	Article	IF	CITATIONS
127	Electric Field–Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment. Journal of Molecular Diagnostics, 2018, 20, 738-742.	2.8	24
128	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2021, 39, 9007-9007.	1.6	24
129	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing. European Journal of Cancer, 2021, 156, 1-11.	2.8	24
130	Facile Preparation of Self-Assembled Hydrogel-like GdPO <sub>4</sub> ·H <sub>2</sub> O Nanorods. Langmuir, 2008, 24, 8309-8313.	3.5	23
131	Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clinical Cancer Research, 2003, 9, 2605-12.	7.0	23
132	Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: Different cytogenetic changes are correlated with genders and smoking habits. Lung Cancer, 2007, 57, 292-301.	2.0	22
133	Epidermal Growth Factor-activated Aryl Hydrocarbon Receptor Nuclear Translocator/HIF-1β Signal Pathway Up-regulates Cyclooxygenase-2 Gene Expression Associated with Squamous Cell Carcinoma. Journal of Biological Chemistry, 2009, 284, 9908-9916.	3.4	22
134	Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT) Journal of Clinical Oncology, 2012, 30, 261-261.	1.6	22
135	Estimating the lifelong health impact and financial burdens of different types of lung cancer. BMC Cancer, 2013, 13, 579.	2.6	21
136	STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production. Angiogenesis, 2013, 16, 207-222.	7.2	21
137	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	1.1	21
138	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research, 2021, 27, 1267-1277.	7.0	21
139	A Clinical Study of 130 Patients with Biliary Tract Cancers and Periampullary Tumors. Oncology, 1996, 53, 488-493.	1.9	20
140	Implantable venous port-related infections in cancer patients. Supportive Care in Cancer, 2004, 12, 197-201.	2.2	20
141	A Randomized, Double-blind, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron plus Dexamethasone Injection for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting. Japanese Journal of Clinical Oncology, 2010, 40, 294-301.	1.3	20
142	The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1478-1485.	6.4	20
143	Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison. Frontiers in Oncology, 2019, 9, 631.	2.8	20
144	Oncogenic Ras-Induced Morphologic Change Is through MEK/ERK Signaling Pathway to Downregulate Stat3 at a Posttranslational Level in NIH3T3 Cells. Neoplasia, 2008, 10, 52-60.	5.3	19

#	Article	IF	CITATIONS
145	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer, 2013, 119, 3043-3051.	4.1	19
146	Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer Journal of Clinical Oncology, 2015, 33, 8063-8063.	1.6	19
147	Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: Adjusting quality-of-life and lead-time bias for utility of surgery. Lung Cancer, 2014, 86, 96-101.	2.0	18
148	Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. PLoS ONE, 2016, 11, e0158125.	2.5	18
149	Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Annals of Hematology, 2012, 91, 1773-1778.	1.8	17
150	Estrogen Receptor Gene Polymorphisms and Lung Adenocarcinoma Risk in Never-Smoking Women. Journal of Thoracic Oncology, 2015, 10, 1413-1420.	1.1	17
151	Phase I study (BLOOM) of AZD3759, a BBB penetrable ECFR inhibitor, in patients with TKI-naÃ <sup>-</sup> ve, EGFRm NSCLC with CNS metastases Journal of Clinical Oncology, 2017, 35, 2006-2006.	1.6	17
152	Upregulation of Tissue Factor by Activated Stat3 Contributes to Malignant Pleural Effusion Generation via Enhancing Tumor Metastasis and Vascular Permeability in Lung Adenocarcinoma. PLoS ONE, 2013, 8, e75287.	2.5	17
153	Activation of the Signal Transducer and Activator of Transcription 3 Pathway Up-Regulates Estrogen Receptor-β Expression in Lung Adenocarcinoma Cells. Molecular Endocrinology, 2011, 25, 1145-1158.	3.7	16
154	Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly (lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway. International Journal of Nanomedicine, 2013, 8, 2689.	6.7	16
155	Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility. Journal of Biomedical Science, 2016, 23, 23.	7.0	16
156	The c.1085A&gt;G Genetic Variant of <i>CSF1R</i> Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages. Clinical Cancer Research, 2017, 23, 6021-6030.	7.0	16
157	Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. Journal of Thoracic Oncology, 2019, 14, 1892-1900.	1.1	16
158	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. British Journal of Cancer, 2019, 121, 131-138.	6.4	16
159	Electric Field–Induced Release and Measurement (EFIRM). Journal of Molecular Diagnostics, 2020, 22, 1050-1062.	2.8	16
160	p53 and c-erbB-2 but Not bcl-2 are Predictive of Metastasis-free Survival in Breast Cancer Patients Receiving Post-mastectomy Adjuvant Radiotherapy in Taiwan. Japanese Journal of Clinical Oncology, 2002, 32, 332-339.	1.3	15
161	Ha-rasOncogene–Induced Stat3 Phosphorylation Enhances Oncogenicity of the Cell. DNA and Cell Biology, 2009, 28, 131-139.	1.9	15
162	Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2011, 68, 1477-1484.	2.3	15

#	Article	IF	CITATIONS
163	EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. Carcinogenesis, 2013, 34, 612-619.	2.8	15
164	Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases. Journal of Molecular Diagnostics, 2014, 16, 486-494.	2.8	15
165	Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice. Quality of Life Research, 2016, 25, 1441-1449.	3.1	15
166	Autophagy regulates vinorelbine sensitivity due to continued Keap1-mediated ROS generation in lung adenocarcinoma cells. Cell Death Discovery, 2018, 4, 33.	4.7	15
167	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.	2.9	15
168	Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. Theranostics, 2022, 12, 340-361.	10.0	15
169	Novel Arylhydrazone-Conjugated Gold Nanoparticles with DNA-Cleaving Ability: The First DNA-Nicking Nanomaterial. Bioconjugate Chemistry, 2007, 18, 1709-1712.	3.6	14
170	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 799-806.	2.3	14
171	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status Journal of Clinical Oncology, 2019, 37, 3011-3011.	1.6	14
172	Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma. Oncotarget, 2014, 5, 6323-6337.	1.8	14
173	Constitutive STAT5 Activation Correlates With Better Survival in Cervical Cancer Patients Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 658-666.	0.8	13
174	The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer. BioMed Research International, 2015, 2015, 1-10.	1.9	13
175	Cost effectiveness of cancer treatment in Taiwan. Journal of the Formosan Medical Association, 2016, 115, 609-618.	1.7	13
176	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875507.	3.2	13
177	<i>EGFR</i> exon 19 inâ€frame deletion and polymorphisms of DNA repair genes in neverâ€smoking female lung adenocarcinoma patients. International Journal of Cancer, 2013, 132, 449-458.	5.1	12
178	Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Scientific Reports, 2017, 7, 3879.	3.3	12
179	Wheat germ agglutinin-induced paraptosis-like cell death and protective autophagy is mediated by autophagy-linked FYVE inhibition. Oncotarget, 2017, 8, 91209-91222.	1.8	12
180	Realâ€world outcomes of NSCLC patients receiving tissue or circulating tumor DNAâ€guided osimertinib treatment. Cancer Medicine, 2019, 8, 5939-5947.	2.8	12

#	Article	IF	CITATIONS
181	Silver-coated zero-valent iron nanoparticles enhance cancer therapy in mice through lysosome-dependent dual programed cell death pathways: triggering simultaneous apoptosis and autophagy only in cancerous cells. Journal of Materials Chemistry B, 2020, 8, 4122-4131.	5.8	12
182	Biocompatible hole scavenger–assisted graphene oxide dots for photodynamic cancer therapy. Nanoscale, 2021, 13, 8431-8441.	5.6	12
183	Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. Environment International, 2021, 147, 105975.	10.0	12
184	Overcoming Radiation Resistance by Iron-Platinum Metal Alloy Nanoparticles in Human Copper Transport 1-Overexpressing Cancer Cells via Mitochondrial Disturbance. International Journal of Nanomedicine, 2021, Volume 16, 2071-2085.	6.7	12
185	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy Journal of Clinical Oncology, 2017, 35, 2069-2069.	1.6	12
186	HER-2/neu raises SHP-2, stops IFN-γ anti-proliferation in bladder cancer. Biochemical and Biophysical Research Communications, 2007, 356, 181-186.	2.1	11
187	The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas. Annals of Hematology, 2008, 87, 985-990.	1.8	11
188	Iron Release Profile of Silica-Modified Zero-Valent Iron NPs and Their Implication in Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 4336.	4.1	11
189	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	1.1	11
190	An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells. Oncotarget, 2015, 6, 20513-20524.	1.8	11
191	Single cell phosphoâ€specific flow cytometry can detect dynamic changes of phosphoâ€Stat1 level in lung cancer cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 1008-1019.	1.5	10
192	Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. PLoS ONE, 2020, 15, e0231413.	2.5	10
193	Expression of DNA repair gene Ku80 in lymphoid neoplasm. European Journal of Haematology, 2005, 74, 481-488.	2.2	9
194	Gastric Perforation Secondary to Regression of Lung Adenocarcinoma After Gefitinib Treatment. Journal of Clinical Oncology, 2013, 31, e6-e8.	1.6	9
195	Syntheses of Platinum–Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs. Chemistry - A European Journal, 2016, 22, 1926-1930.	3.3	9
196	Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC. Medicine (United States), 2019, 98, e16766.	1.0	9
197	EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. Journal of the Formosan Medical Association, 2021, 120, 1729-1739.	1.7	9
198	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without <i>EGFR</i> -activating mutations Journal of Clinical Oncology, 2022, 40, 9017-9017.	1.6	9

#	Article	IF	CITATIONS
199	Nucleocytoplasmic transport blockage by SV40 peptide-modified gold nanoparticles induces cellular autophagy. International Journal of Nanomedicine, 2012, 7, 5215.	6.7	8
200	CDKN1A-mediated responsiveness ofMLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. International Journal of Cancer, 2014, 135, 751-762.	5.1	8
201	Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells. Cancer Letters, 2014, 349, 144-151.	7.2	8
202	Comparison of expected health impacts for major cancers: Integration of incidence rate and loss of quality-adjusted life expectancy. Cancer Epidemiology, 2015, 39, 126-132.	1.9	8
203	Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1817-1826.	1.7	8
204	Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations Journal of Clinical Oncology, 2022, 40, 430-430.	1.6	8
205	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 760686.	2.8	8
206	The down regulation of target genes by photo activated DNA nanoscissors. Biomaterials, 2010, 31, 6545-6554.	11.4	7
207	Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoringâ€Mass Spectrometry. Proteomics - Clinical Applications, 2020, 14, e1900095.	1.6	7
208	The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy. Scientific Reports, 2022, 12, 3319.	3.3	7
209	EBER-1 positive diffuse large cell lymphoma presenting as lupus nephritis. Lupus, 2003, 12, 486-489.	1.6	6
210	Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. Lung Cancer, 2021, 158, 137-145.	2.0	6
211	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-NaÃ <sup>-</sup> ve Patients withÂEGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Targeted Oncology, 2022, 17, 1-13.	3.6	6
212	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures Journal of Clinical Oncology, 2022, 40, 9015-9015.	1.6	6
213	Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapyâ€based <sup>18</sup> Fâ€FDG PET/CT in stage III nonâ€small cell lung cancer. Kaohsiung Journal of Medical Sciences, 2019, 35, 151-159.	1.9	5
214	Clinical Frailty Scale in Predicting Postoperative Outcomes in Older Patients Undergoing Curative Surgery for Urologic Malignancies: A Prospective Observational Cohort Study. Urology, 2020, 144, 38-45.	1.0	5
215	Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC. Biomedicines, 2021, 9, 243.	3.2	5
216	Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers Journal of Clinical Oncology, 2017, 35, 2580-2580.	1.6	5

#	Article	IF	CITATIONS
217	FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer. Scientific Reports, 2022, 12, 241.	3.3	5
218	Successful Matched-Unrelated Bone Marrow Transplantation in a Patient With Beta-Thalassemia Major. Journal of Pediatric Hematology/Oncology, 2002, 24, 579-581.	0.6	4
219	High-dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients with Nasopharyngeal Cancer: a Feasibility Study. Japanese Journal of Clinical Oncology, 2003, 33, 331-335.	1.3	4
220	Cytomegalovirus and Epstein–Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2011, 90, 113-114.	1.8	4
221	Successful AZD9291 Therapy in Advanced Non–Small Cell Lung Cancer after Failure of HM61713. Journal of Thoracic Oncology, 2017, 12, e72-e74.	1.1	4
222	Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. Frontiers in Oncology, 2021, 11, 753788.	2.8	4
223	CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes. International Journal of Molecular Sciences, 2021, 22, 12565.	4.1	4
224	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics, 2021, 11, 2308.	2.6	4
225	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer. Lung Cancer, 2022, 166, 170-177.	2.0	4
226	An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan. Oncology, 2013, 84, 299-304.	1.9	3
227	A novel dielectrophoresis-based microfluidic chip for antibody-free isolation of circulating tumor cells from blood. , 2015, , .		3
228	Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors. Oncologist, 2021, 26, e567-e579.	3.7	3
229	The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	3.2	3
230	Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report. JTO Clinical and Research Reports, 2021, 2, 100202.	1.1	3
231	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2021, 2, 100206.	1.1	3
232	Development of a novel ALK rearrangement screening test for non–small cell lung cancers. PLoS ONE, 2021, 16, e0257152.	2.5	3
233	Firstâ€ŀine treatment with irreversible tyrosine kinase inhibitors associated with longer <scp>OS</scp> in <scp><i>EGFR</i></scp> mutationâ€positive nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 287-296.	1.9	3
234	Improved survival in patients with unresectable stage <scp>III <i>EGFR</i></scp> â€mutant adenocarcinoma with upfront <scp>EGFR</scp> â€tyrosine kinase inhibitors. Thoracic Cancer, 2022, 13, 182-189.	1.9	3

#	Article	IF	CITATIONS
235	Cytomegalovirus-related neutropenic enterocolitis with negative CMV antigenemia as the initial presentation in an acute myeloid leukemia patient. Annals of Hematology, 2009, 88, 279-280.	1.8	2
236	Oral vinorelbine: a Better Choice for Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. Journal of Solid Tumors, 2012, 2, .	0.1	2
237	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT) Journal of Clinical Oncology, 2014, 32, 4534-4534.	1.6	2
238	EFIRM liquid biopsy (eLB) <i>: D</i> etection of ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology, 2018, 36, e24062-e24062.	1.6	2
239	281â€JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC). , 2020, , .		2
240	Using 2-step PCR and restriction endonuclease digestion to detect K-ras mutation in paraffin-embedded tissues: Is it reliable?. , 1998, 12, 168-171.		1
241	Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. Lung Cancer, 2018, 120, 149-151.	2.0	1
242	Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Scientific Reports, 2021, 11, 4834.	3.3	1
243	Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress) Journal of Clinical Oncology, 2021, 39, TPS256-TPS256.	1.6	1
244	A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy Journal of Clinical Oncology, 2017, 35, 2531-2531.	1.6	1
245	Technical validation of the electric field-induced release and measurement (EFIRM) assay for the detection of <i>EGFR</i> mutations in circulating cell free DNA in plasma and saliva Journal of Clinical Oncology, 2018, 36, e24172-e24172.	1.6	1
246	Photoactive Compound-Triplex-Forming Oligonucleotide Linked Gold Nanoparticle as an Artificial Gene Specific DNA Cleaver Assembly. , 2008, , .		0
247	Germ Cell Tumor With Somatic-Type Malignancy Presenting As Right Facial Swelling in a Young Woman. Journal of Clinical Oncology, 2011, 29, e699-e701.	1.6	0
248	IL-6 as a potential biomarker in lung cancer. Lung Cancer Management, 2014, 3, 237-240.	1.5	0
249	Development of the CKâ€MBâ€1 trastuzumabâ€resistant HER2â€positive breast cancer cell line and xenograft animal models. Cancer Medicine, 2021, 10, 2370-2379.	2.8	0
250	Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors Journal of Clinical Oncology, 2014, 32, TPS2631-TPS2631.	1.6	0
251	Enhanced antitumor activity of rapamycin and genipin, a UCP-2 inhibitor, in lung cancer Journal of Clinical Oncology, 2015, 33, e13595-e13595.	1.6	0
252	Ipilimumab in treating Asian patient with advanced melanoma: The preliminary report of Taiwan ipilimumab extended access program group Journal of Clinical Oncology, 2015, 33, e20069-e20069.	1.6	0

#	Article	IF	CITATIONS
253	Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors Journal of Clinical Oncology, 2016, 34, 745-745.	1.6	0
254	miR-200c in extracellular vesicles as a circulating biomarker of EGFR-TKI response and a mediator of EGFR-TKI sensitivity in heterogeneous NSCLC Journal of Clinical Oncology, 2019, 37, e20547-e20547.	1.6	0
255	Title is missing!. , 2020, 15, e0231413.		0
256	Title is missing!. , 2020, 15, e0231413.		0
257	Title is missing!. , 2020, 15, e0231413.		0
258	Title is missing!. , 2020, 15, e0231413.		0
259	Title is missing!. , 2020, 15, e0231413.		0
260	Title is missing!. , 2020, 15, e0231413.		0